Pharmaceutical News

Law360 Names BHAG Attorney Brent Wisner Titan of the Plaintiffs Bar

May 7, 2018 – Los Angeles, California - - Legal news media company Law360 named Baum, Hedlund, Aristei & Goldman attorney R. Brent Wisner a Titan of the Plaintiffs Bar. Wisner was one of ten attorneys Law360 profiled for earning significant legal victories in 2017. According to Law360, the attorneys [...]

By | 2018-06-06T12:45:52+00:00 May 7th, 2018|Blog, Paxil News, Pharma News, Press Releases, R. Brent Wisner|

Widow Maintains GSK Liable for Suicide in Paxil Lawsuit Appeal

March 1, 2018 – Chicago, Illinois — The widow of a Chicago lawyer who took his own life while taking a generic version of Paxil (paroxetine), a GlaxoSmithKline (GSK) antidepressant, told a federal appeals court that a jury’s verdict holding GSK liable for her husband’s suicide should stand. In the [...]

By | 2018-04-11T10:51:38+00:00 March 1st, 2018|Blog, Paxil News, Pharma News, Press Releases, R. Brent Wisner|

Researchers Seek Retraction of MD-18 Celexa Study

Feb. 23, 2018 – Los Angeles, California – A group of researchers sent a letter this week to Dr. Robert Freedman, Editor of the American Journal of Psychiatry, calling for the retraction of a Celexa study the researchers claim is rife with “serious misrepresentations.” The study, known as the MD-18 ‘Wagner’ [...]

Baum Hedlund Urges DOJ to Reopen Investigation re Celexa / Lexapro Clinical Trials

Boston, Massachusetts – February 8, 2018 - - The law firm of Baum, Hedlund, Aristei & Goldman has sent a letter and memorandum to the U.S. Attorney’s Office (USAO) for the District of Massachusetts calling for the reopening of its investigation and prosecution of Forest Laboratories Inc. and its subsidiary, [...]

Acthar Class Action Accuses Mallinckrodt of Inflating Price 85,000%

Los Angeles, California - - A class action lawsuit filed on behalf of numerous Medicare Advantage Organizations (MAOs) accuses pharmaceutical manufacturer Mallinckrodt (MNK) of engaging in a scheme to drastically inflate the price and reduce competition for its drug H.P. Acthar Gel (Acthar), a drug primarily prescribed for infants with [...]

Judge Refuses GlaxoSmithKline Motion for New Paxil Suicide Trial

Chicago, Illinois -- A federal judge has entered judgment against GlaxoSmithKline (“GSK”) affirming the April 20, 2017 jury verdict in favor of Wendy Dolin who alleged her husband’s 2010 suicide was the result of side effects he suffered while taking generic Paxil (paroxetine). Following the jury’s $3,000,000 verdict in Dolin’s [...]

By | 2017-09-15T16:16:20+00:00 September 14th, 2017|Blog, Paxil News, Pharma News, Press Releases, Michael L. Baum, R. Brent Wisner|

Minnesota Woman Who Lost $156,000 Files Abilify Gambling Lawsuit

A few years ago, long before she would even think about filing her Abilify gambling lawsuit, Denise Miley had what appeared to be the perfect life. She and her husband lived in a beautiful home in Maple Grove, Minnesota, with their four sons. Her career as a CPA was enjoyable [...]

By | 2017-06-20T16:11:20+00:00 May 23rd, 2017|Abilify News, Pharma News|

$3M Jury Verdict Against GSK in Landmark Paxil Suicide Case

April 20, 2017, Chicago, Illinois - - A federal jury has sided with the widow of a deceased Chicago attorney in her generic Paxil suicide lawsuit against GlaxoSmithKline (GSK), ordering the pharmaceutical giant to pay $3 million. The jury verdict resolves allegations in the trial of Dolin v. Smithkline Beecham [...]

Bristol-Myers Squibb Will Pay $19.5 Billion in Abilify Settlement

Last month, pharmaceutical company Bristol-Myers Squibb agreed to pay $19.5 million to settle a multi-state lawsuit that charged the company with improper marketing of the atypical antipsychotic Abilify. Abilify is made by Otsuka America Pharmaceutical, Inc. and marketed and promoted in the United States by Bristol-Myers Squibb. Money from the [...]

By | 2018-07-17T12:00:22+00:00 January 20th, 2017|Abilify News, Pharma News|

U.S. Abilify Warning Label Now Includes Compulsive Gambling

The popular antipsychotic Abilify (aripiprazole) received approval from the U.S. Food and Drug Administration (FDA) in 2002 for the treatment of bipolar disorder, schizophrenia and other major depressive disorders. Since then, there have been over 180 reported instances of impulse control problems among Abilify users, including compulsive gambling, shopping, binge [...]

By | 2017-06-20T16:12:01+00:00 September 26th, 2016|Abilify News, Pharma News|